Published in final edited form as:

Tetrahedron Lett. 2014 October 1; 55(40): 5570–5571. doi:10.1016/j.tetlet.2014.08.028.

An efficient synthesis of 3-(*N*-piperidinemethyl)-2, 2, 5, 5-tetramethyl-1-oxy-3-pyrroline, a promising radioprotector for cancer radiotherapy

Haitao Wu^{a,*}, Vincent Coble^a, Olga Vasalatiy^a, Rolf E. Swenson^a, Murali C. Krishna^b, and James B. Mitchell^b

^aImaging Probe Development Center, National Heart, Lung, and Blood Institute, National Institutes of Health

^bRadiation Biology Branch, Center for Cancer Research, National Cancer Institute. National Institutes of Health

Abstract

Nitroxides can ameliorate the toxic effects of radiation during cancer therapy. Nitroxides are paramagnetic and can be used in magnetic resonance imaging (MRI) and electron paramagnetic resonance imaging (EPRI) to monitor *in vivo* oxidative stress status. Compound **5** (3-(*N*-piperidinemethyl)-2, 2, 5, 5-tetramethyl-1-oxy-3-pyrroline) was found to be the most effective nitroxide radioprotector. An efficient synthesis for this promising radioprotector was developed.

Keywords

Nitroxide; redox; radioprotector; MRI; EPRI

Protection from radiation exposure is important for radiation cancer treatment or a nuclear accident. Cancer is the second leading cause of death in the United States, exceeded only by heart disease. The estimated number of new cancer cases is 1.66 million and about 580,350 people are expected to die in US alone in 2013.¹ The death rates of cancer did not change much over the past 80 years except for lung and bronchus cancers. It is well known that cancer can be treated with ionizing radiation, but the inevitable normal tissues exposure during cancer radiotherapy or a nuclear accident can promote carcinogenesis and a variety of toxicities.^{2, 3} Pre-exposure administration of a radiation protective drug can reduce radiation damage by ameliorating the toxic effects of radiation. Preclinical studies in mice have shown that administration of Tempol (1-oxy-2, 2, 6, 6-tetramethyl-4-hydroxypiperidine) decreases the severity of xerostomia (dry mouth) after salivary gland irradiation and

*Corresponding author. Tel.: 1-301-217-5763; Fax: 1-301-217-4078; wuh3@mail.nih.gov.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Supplementary data Experimental procedures and complete spectral data and the copies of ¹H and ¹³C NMR spectra of all intermediates and final product are available. Supplementary data associated with this article can be found, in the online version.

increases the LD50/30 after whole-body irradiation.^{4–6} Nitroxides are paramagnetic and their pharmacokinetics can therefore be monitored with magnetic resonance imaging (MRI), electron paramagnetic resonance imaging (EPRI), and their concentration in tissues can be quantified.^{5, 6} The *in vivo* redox reactions among nitroxides, reactive oxygen species and intracellular antioxidants can also be used for redox imaging study. Formation of diamagnetic hydroxylamine from nitroxide redox reaction results in signal loss in T1-weighted MRI scan which can provide an imaging-based assay of tissue redox status.⁷ Based on the initial findings on the radioprotective effects of the model compound Tempol^{4, 8, 9} and a systematic *in vitro* survey of a variety of nitroxide-related radioprotectors,¹⁰ compound 3-(*N*-piperidinemethyl)-2, 2, 5, 5-tetramethyl-1-oxy-3-pyrroline, **5** was found to be the most effective radioprotector against lethal doses of radiation in mice.¹¹ In addition, the compound readily passes the blood–brain barrier (BBB). A previous synthesis of compound **5** produced about 5% overall yield over a 6-step synthesis (Scheme 1).¹⁰ Following this procedure we noticed a UV invisible byproduct next to product **5** on TLC plate that can be detected by I₂ staining. The separation of the two products was difficult. In addition the product purity cannot be accurately characterized by NMR due to the paramagnetic property of the product or by HPLC due to the weak UV absorption of the byproduct and the similarity of their retention times. The byproduct was found to be hydroxylamine compound **7**. Contamination of the diamagnetic hydroxylamine would adversely affect the MR and EPR imaging quality. The availability of a more convenient and efficient synthesis method of this promising agent would be beneficial.

We found that the Favorskii rearrangement of 3, 5-dibromo-4-oxo-2, 2, 6, 6-tetramethylpiperidine **2** could be done in the presence of piperidine to form the piperidine derivative **3** directly in 89% yield (Scheme 2).¹² The conversion of the amine **3** to the nitroxide **4** was carried out in 90% yield by stirring with the H₂O₂ and Na₂WO₄ oxidants at room temperature for 2 days. Amide carbonyl reduction of **4** using LiAlH₄ instead of Red-Al also gave an improved yield of 92%.¹³ However trace amount of hydroxylamine byproduct **7** (< 5%) was still present. The byproduct can be completely converted to product **5** by adding *m*-chloroperoxybenzoic acid (*m*-CPBA) oxidant to the reaction mixture and then stirring for 2 h; *m*-CPBA can be easily removed afterward by liquid extraction workup in basic aqueous solution. The improved synthesis route to **5** reduced the total synthesis to four steps and increased the overall yield to 65% while completely eliminating the contamination of hydroxylamine byproduct **7**. The purification procedures were also simplified.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported [in part] by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research and through intramural research funds for the Imaging Probe Development Center as administered by the National Heart, Lung, and Blood Institute.

References and Notes

1. American Cancer Society Cancer Facts & Figs. American Cancer Society; Atlanta: 2013.
2. Henderson TO, Amsterdam A, Bhatia S, Hudson MM, Meadows AT, Neglia JP, Diller LR, Constine LS, Smith RA, Mahoney MC, Morris EA, Montgomery LL, Landier W, Smith SM, Robison LL, Oeffinger KC. *Annals of Internal Medicine*. 2010; 152:444. [PubMed: 20368650]
3. DiCarlo AL, Maher C, Hick JL, Hanfling D, Dainiak N, Chao N, Bader JL, Coleman CN, Weinstock DM. *Disaster Medicine and Public Health Preparedness*. 2011; 5:S32. [PubMed: 21402810]
4. Hahn SM, Tochner Z, Krishna CM, Glass J, Wilson L, Samuni A, Sprague M, Venzon D, Glatstein E, Mitchell JB, Russo A. *Cancer Research*. 1992; 52:1750. [PubMed: 1551104]
5. Cotrim AP, Hyodo F, Matsumoto KI, Sowers AL, Cook JA, Baum BJ, Krishna MC, Mitchell JB. *Clinical Cancer Research*. 2007; 13:4928. [PubMed: 17699873]
6. Cotrim AP, Sowers AL, Lodde BM, Vitolo JM, Kingman A, Russo A, Mitchell JB, Baum BJ. *Clinical Cancer Research*. 2005; 11:7564. [PubMed: 16243832]
7. Davis RM, Mitchell JB, Krishna MC. *Anti-Cancer Agents in Medicinal Chemistry*. 2011; 11:347. [PubMed: 21434855]
8. Hahn SM, Sullivan FJ, DeLuca AM, Krishna CM, Wersto N, Venzon D, Russo A, Mitchell JB. *Free Radical Biology and Medicine*. 1997; 22:1211. [PubMed: 9098095]
9. Mitchell JB, Degraff W, Kaufman D, Krishna MC, Samuni A, Finkelstein E, Ahn MS, Hahn SM, Gamson J, Russo A. *Archives of Biochemistry and Biophysics*. 1991; 289:62. [PubMed: 1654848]
10. Krishna MC, DeGraff W, Hankovszky OH, Sár CP, Kálai T, Jek J, Russo A, Mitchell JB, Hideg K. *Journal of Medicinal Chemistry*. 1998; 41:3477. [PubMed: 9719601]
11. Davis RM, Sowers AL, DeGraff W, Bernardo M, Thetford A, Krishna MC, Mitchell JB. *Free Radical Biology and Medicine*. 2011; 51:780. [PubMed: 21664459]
12. Stork SW, Makinen MW. *Synthesis*. 1999; 8:1309.
13. Powell JH, Johnson EM, Gannett PM. *Molecules*. 2000; 5:1244.

Highlights

An improved strategy to synthesize a nitroxide radio protector is described.

The previously reported six-step synthesis procedure is reduced to four steps.

A number of synthetic steps and over all yield are significantly improved.

The simplified synthesis conveniently removes the major byproduct contamination.

Scheme 1.

Reagents and conditions: (i) Br₂, AcOH, 12h, 90%; (ii) NaOMe in MeOH, rt, 1h, 40%; (iii) Red-Al in toluene, 40°C, 1h, 61%; (iv) H₂O₂, Na₂WO₄ in MeOH, 0°C-rt, 36h, 50%; (v) MsCl, TEA in DCM, 0°C-rt, 3h, 87%; (vi) piperidine, NaH in DMF, 0°C-rt, 4h, 47%.

Scheme 2.

Reagents and conditions: (i) Br₂, AcOH, 12h, 90%; (ii) Piperidine, TEA-H₂O, rt, 6h and then 50°C, 6h, 89%; (iii) H₂O₂, Na₂WO₄ in H₂O, rt, 2d in dark, 90%; (iv) LiAlH₄ in THF, rt, 24h, 92%; (v) *p*-TSA in ether, rt, 96%; (vi) *m*-CPBA, rt, 2h.